Mild Cognitive Impairment and Neurofeedback: A Randomized Controlled Trial

Yotam Lavy1,2, Tzvi Dwolatzky3,4, Zeev Kaplan2

  • 1Ophtalmology Department, Soroka Medical Centre, Beersheba, Israel.

Insights

EEG neurofeedback shows promise for improving memory in mild cognitive impairment (MCI). This early intervention may help prevent cognitive decline and Alzheimer's disease (AD) progression.

Area of Science:

  • Neuroscience
  • Cognitive Science
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) often precedes dementia, particularly Alzheimer's Disease (AD).
  • Individuals with amnestic MCI have a significantly higher risk of developing AD.
  • MCI represents an early, detectable stage for therapeutic intervention and prevention strategies.

Purpose of the Study:

  • To investigate the efficacy of electroencephalography (EEG)-based neurofeedback in enhancing memory performance in patients with MCI.
  • To explore the potential of neurofeedback in reversing common EEG alterations observed in MCI patients.
  • To address memory decline, a primary symptom and predictor of cognitive deterioration in MCI and AD.

Main Methods:

  • Utilized EEG-based neurofeedback to improve memory performance in MCI patients.
  • Implemented a protocol to enhance upper alpha band activity through positive feedback.
  • Compared an experimental group receiving targeted neurofeedback with a sham group receiving random feedback.

Main Results:

  • Significant memory performance improvement observed in the experimental neurofeedback group compared to the sham group.
  • Memory enhancement in the experimental group was sustained for at least one month post-intervention.
  • EEG-based neurofeedback demonstrated a positive impact on memory function in MCI subjects.

Conclusions:

  • EEG neurofeedback presents a promising, affordable, and novel therapeutic approach for MCI.
  • This method may help mitigate memory decline associated with mild cognitive impairment.
  • Neurofeedback could be a valuable tool in managing early-stage cognitive deterioration and potentially delaying AD progression.

Related Concept Videos